← All trials
NCT05562362
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2020
- Primary completion
- Nov 12, 2020
- Completion date
- Nov 12, 2020
- First posted
- Sep 30, 2022
- Last posted
- Sep 30, 2022
- Enrollment
- 47
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Travere Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.